NASDAQ:VIST - Visterra Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Visterra Inc is a United States-based biotechnology company. The Company uses its Atomic Interaction Network analysis to identify disease targets and design effective therapeutics. The Company's technology is based on its Hierotope Platform, which identifies an area, or epitope, on the target protein, glycoprotein or glycan that is fundamental to its structure and function. The Company's Hierotope Platform is able to identify the region of the protein, or epitope, which is structurally constrained, and thus prevented from mutation over time or under immunological or therapeutic pressure. Its technology for creating potent and therapeutics is powered by the Company's computational tools and techniques, the core of which is called Atomic Interaction Network (AIN) analysis.

Receive VIST News and Ratings via Email

Sign-up to receive the latest news and ratings for VIST and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:VIST
Previous Symbol
CUSIPN/A
Phone+1-617-4981070

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding SharesN/A
Market Cap$0.00
OptionableNot Optionable

Visterra (NASDAQ:VIST) Frequently Asked Questions

What is Visterra's stock symbol?

Visterra trades on the NASDAQ under the ticker symbol "VIST."

Has Visterra been receiving favorable news coverage?

Press coverage about VIST stock has trended negative this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Visterra earned a news impact score of -2.6 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the next few days.

When did Visterra IPO?

(VIST) raised $51 million in an IPO on the week of January 30th 2017. The company issued 3,900,000 shares at $12.00-$14.00 per share. Leerink Partners and Stifel acted as the underwriters for the IPO and Needham & Company, Wedbus and PacGrow were co-managers.

How do I buy shares of Visterra?

Shares of VIST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Visterra's official website?

The official website for Visterra is http://www.visterrainc.com/.

How can I contact Visterra?

Visterra's mailing address is 1 Kendall Sq Ste B3301, CAMBRIDGE, MA 02139-1604, United States. The biotechnology company can be reached via phone at +1-617-4981070.


MarketBeat Community Rating for Visterra (NASDAQ VIST)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  29 (Vote Outperform)
Underperform Votes:  43 (Vote Underperform)
Total Votes:  72
MarketBeat's community ratings are surveys of what our community members think about Visterra and other stocks. Vote "Outperform" if you believe VIST will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VIST will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/17/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel